What is Desjardins’ Estimate for TSE:INO Q1 Earnings?

Inovalis Real Estate Investment Trust (TSE:INO) – Investment analysts at Desjardins issued their Q1 2025 earnings per share (EPS) estimates for Inovalis Real Estate Investment Trust in a research note issued to investors on Wednesday, April 2nd. Desjardins analyst A. Leon forecasts that the company will post earnings of $0.01 per share for the quarter. Desjardins also issued estimates for Inovalis Real Estate Investment Trust’s Q1 2025 earnings at $0.01 EPS, Q2 2025 earnings at $0.02 EPS, Q3 2025 earnings at $0.03 EPS, Q4 2025 earnings at $0.02 EPS and Q4 2025 earnings at $0.02 EPS.

Inovalis Real Estate Investment Trust Stock Performance

Inovalis Real Estate Investment Trust Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.